Citius Pharmaceuticals, Inc.
-$31.69M- Market cap
- $16.13M
- Debt
- +-$6.11M
- Cash
- −$41.71M
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: CTXR stock price at premium vs NE $0.59 current versus $0.01 implied using P/S multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at NE's multiple
Implied fair value · at CTXR's multiple
Snapshot Sep 4, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Pricing power
Operating leverage
Multiple discount
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: CTXR FY 2022 (ended Sep 30, 2022) · NE FY 2025 (ended Dec 31, 2025). Fiscal years are not aligned.
Trendline
Eight fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Capital structure 161% equity / -61% debt · EV / EBITDA 0.96x
Capital structure 79% equity / 21% debt · EV / Revenue 2.67x · EV / EBITDA 20.18x
NE carries the larger enterprise value at $8.79B against -$31.69M; CTXR trades on the lower EV / EBITDA multiple (0.96x vs 20.18x).
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
Citius Pharmaceuticals, Inc. · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Noble Corporation plc · implied price per share
Five annual free-cash-flow observations are required for the filing-backed baseline.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
-0.06x
0.43x
Net debt / EBITDA
Leverage against operating earnings
1.45x
3.46x
Cash and equivalents
Liquid reserves on the balance sheet
$41.71M
$471.40M
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Zomedica Corp.
CTXR vs ZOM
Aquestive Therapeutics, Inc.
CTXR vs AQST
ACADIA PHARMACEUTICALS INC
CTXR vs ACAD
AMGEN INC
CTXR vs AMGN
GILEAD SCIENCES, INC.
CTXR vs GILD
AbbVie Inc.
CTXR vs ABBV
Transocean Ltd.
CTXR vs RIG
Valaris Ltd
CTXR vs VAL
Seadrill Ltd
CTXR vs SDRL
VALERO ENERGY CORP/TX
CTXR vs VLO
ONEOK INC /NEW/
CTXR vs OKE
HALLIBURTON CO
CTXR vs HAL
-$6.11M
$1.98B
LLM-powered synthesis
An on-demand narrative read of the same deterministic data.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.